Smith & NephewLSE:SN. -4.63%84 EV-to-FCF is 17.85 as of Jul. 01, 2026, which is 46% below its 10-year median of 32.99. GuruFocus rates LSE:SN. with a GF Score™ of 84/100 and a GF Value™ of £11.87 (Fairly Valued). The stock has 3 warning signs investors should review. Among 418 Medical Devices & Instruments companies, Smith & Nephew ranks better than 61.72% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Smith & Nephew's Enterprise Value is £11,313 Mil.
Smith & Nephew's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was £634 Mil. Therefore, Smith & Nephew's EV-to-FCF for today is 17.85.
The historical rank and industry rank for Smith & Nephew's EV-to-FCF or its related term are showing as below:
LSE:SN.'
s EV-to-FCF Range Over the Past 10 Years
Min: 17.85 Med: 32.99 Max: 150
Current: 17.85
During the past 13 years, the highest EV-to-FCF of Smith & Nephew was 150.00. The lowest was 17.85. And the median was 32.99.
LSE:SN.'s EV-to-FCF is ranked better than 61.72% of 418
companies
in the Medical Devices & Instruments industry
Industry Median: 22.895
vs LSE:SN.: 17.85
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Smith & Nephew's PE Ratio (TTM) for today is calculated as:
Smith & Nephew's share price for today is £10.905.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Smith & Nephew's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was £0.531.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Smith & Nephew EV-to-FCF Related Terms
Smith & Nephew EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Smith & Nephew's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Smith & Nephew's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Smith & Nephew EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Smith & Nephew's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Smith & Nephew's EV-to-FCF falls into.
Smith & Nephew's current Enterprise Value is £11,313 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Smith & Nephew's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was £634 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Smith & Nephew (LSE:SN.) has a EV-to-FCF of 17.85 as of Jul. 01, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Smith & Nephew and its competitors. This is 46% below median its historical median of 32.99. Over the past decade, Smith & Nephew's EV-to-FCF has ranged from 17.85 to 150.00. According to the industry distribution chart, Smith & Nephew ranks #160 out of 418 companies in the Medical Devices & Instruments industry, placing it in the top 38.3%.
Is Smith & Nephew's EV-to-FCF too high?
Smith & Nephew's current EV-to-FCF of 17.85 is 46% below median its 10-year median of 32.99. Over the past 10 years, this metric has ranged from a low of 17.85 to a high of 150.00. The Medical Devices & Instruments industry median EV-to-FCF is 22.90. Smith & Nephew's value of 17.85 is 22% below this industry median. Based on the distribution chart, Smith & Nephew ranks #160 out of 418 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Smith & Nephew has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Smith & Nephew's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Smith & Nephew ranks #160 out of 418 companies for EV-to-FCF. This puts Smith & Nephew in the upper half of its industry. The industry median EV-to-FCF is 22.90. Smith & Nephew's value of 17.85 is 22% below this benchmark. Historically, Smith & Nephew's own EV-to-FCF has ranged from 17.85 to 150.00 over the past decade. While the company's 10-year median is 32.99 vs. the industry median of 22.90, Smith & Nephew has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 22.90, based on 418 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Smith & Nephew's current EV-to-FCF of 17.85 is 22% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Smith & Nephew and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 22.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Smith & Nephew's current EV-to-FCF is 17.85, which is 46% below median its own 10-year median of 32.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Smith & Nephew stock overvalued right now?
Based on GuruFocus' analysis, Smith & Nephew (LSE:SN.) is currently considered Fairly Valued. The stock's GF Value™ is £11.87, compared to a current price of £10.91 — trading 8.1% below its estimated fair value. The current EV-to-FCF is 17.85, which is 46% below median its 10-year median of 32.99 and 22% below the Medical Devices & Instruments industry median of 22.90. Smith & Nephew's overall GF Score™ is 84/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Smith & Nephew (LSE:SN.), the current EV-to-FCF is 17.85 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Smith & Nephew (LSE:SN.) Overvalued in 2026?
Based on GuruFocus' analysis, Smith & Nephew stock appears to be undervalued.
The current stock price of £10.91 is trading 8.1% below its estimated GF Value™ of £11.87.
GuruFocus considers Smith & Nephew to be Fairly Valued.
Key valuation signals for LSE:SN.:
EV-to-FCF: 17.85 (46% below median its 10-year median of 32.99)
GF Value™: £11.87 vs. price of £10.91 (8.1% below fair value)
Industry Position: 22% below the Medical Devices & Instruments median (#160 of 418)
No single metric tells the full story. See the LSE:SN. stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
84GF Score
Get the complete analysis for LSE:SN.
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:SN. has been successfully added to your 
